CRPC

First Patient Treated in Cohort 4 of Clarity Pharmaceuticals’ SECuRE Trial
Following the announcement that Clarity Pharmaceuticals’ SECuRE trial advanced to a multidose phase, the first patients in cohort 4 received 67Cu-SAR-bisPSMA at 12 GBq. The trial is investigating the potential of 64Cu/67Cu-SAR-bisPSMA in patients with metastatic castration-resistant prostate cancer (mCRPC). ...
Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Advertisement
Latest News